A 60-year-old African American man presented to our hospital with a 6-month history of progressively worsening fatigue, 30-pound weight loss, jaundice, pruritis, dark urine, and straining on urination. He reported no previous intravenous drug use. His physical exam revealed nontender lymphadenopathy involving the anterior cervical, axillary, and inguinal areas. The rectal exam revealed irregularity of the left prostatic border. Initial laboratory results were significant for hyperbilirubinemia (9.3 mg/dL) with direct bilirubin predominance (7.9 mg/dL), as well as elevated aspartate aminotransferase (200 IU/L), alanine aminotransferase (169 IU/L), and alkaline phosphatase (1803 IU/L) with predominant hepatic origin evidenced by elevated liver isoenzyme (1352 IU/L) and γ-glutamyltransferase (2152 IU/L). Hepatitis, HIV, autoimmune, and acetaminophen toxicity evaluations were negative. Prostate-specific antigen was elevated (41.4 ng/mL).
signal intensity lesions scattered throughout the liver, thought to represent hepatic cysts, with no intrahepatic or extrahepatic biliary duct dilatation to suggest obstruction.
The patient underwent fine needle aspiration of the left external iliac lymph nodes; pathology revealed malignant cells consistent with metastatic adenocarcinoma of prostatic origin. Immunostaining for prostate-specific antigen ( Figure 1A ) and CD-10 ( Figure 1B ) were positive.
Following oncology consultation, the patient began androgen deprivation therapy for inoperable metastatic prostate cancer. He took bicalutamide, an androgen receptor blocker, for 4 days during the hospitalization but stopped for the next 23 days since he failed to pick up the medications. Bicalutamide was restarted on treatment day 28. Additionally, he received leuprolide, a GnRH analog, on treatment day 49 and day 71. The patient responded well to the treatment as the liver function tests normalized over time ( Figure 2 ). Improvement in laboratory values paralleled 
Discussion
Stauffer's syndrome, a paraneoplastic syndrome resulting in liver enzyme derangement, was initially introduced by Dr Maurice H. Stauffer, who witnessed a reversal of hepatic dysfunction following a resection of renal cell carcinoma. 1 Since its original discovery, more literature has emerged supporting Stauffer's syndrome in various types of neoplasms. Thus far, there are only 6 reported cases of adenocarcinoma as a source of Stauffer's syndrome. [2] [3] [4] [5] [6] [7] Only one case of metastatic prostate adenocarcinoma demonstrated partial resolution of hepatic dysfunction with androgen deprivation therapy. 2 Our case is the first report, to our knowledge, of metastatic prostate adenocarcinoma with CD-10-positive stain that responded to androgen deprivation therapy, resulting in a complete reversal of hepatic dysfunction in all measured categories. Of note, the total bilirubin level reversed early in his course, despite interruption of androgen deprivation therapy, which may be explained by bicalutamide's long half-life of 6 days. The pathophysiology of Stauffer's syndrome remains largely unexplained, but interleukin-6 is thought to play a crucial role. 8 Overall, Stauffer's syndrome is a rare complication of many types of cancer; however, liver dysfunction without obvious cause in the presence of concomitant neoplasm must be readily recognized as a possible paraneoplastic process. 
